CVC and GBL to Acquire Italian Pharma Giant Recordati for $12 Billion

Private equity giant CVC Capital Partners Plc and Belgian investment firm Groupe Bruxelles Lambert (GBL) have submitted a bid to acquire Italian pharmaceutical manufacturer Recordati SpA. The deal values Recordati at over $12 billion, making it one of the largest healthcare sector transactions in Europe this year. Recordati is an Italian pharmaceutical company specializing in rare diseases and cardiovascular drugs. The joint offer from CVC and GBL aims to purchase the company's shares for cash. If completed, Recordati's current management team is expected to remain with the company. This acquisition reflects the consolidation trend in the European pharmaceutical sector. CVC and GBL aim to capitalize on Recordati's strong growth potential and expand their portfolios. The deal is subject to regulatory approvals and is expected to close within 2024. Recordati's shares rose on the Milan Stock Exchange following the announcement. Investors believe the deal will enhance the company's value and provide a significant premium to shareholders. CVC and GBL plan to strengthen Recordati's R&D capabilities and existing product portfolio. This is not investment advice.